Zacks.com on MSN16 小时
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).
Medscape21 小时
Dupilumab Beneficial When Antihistamines Fall Short for Chronic Spontaneous Urticaria
Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...
Stocktwits on MSN17 小时
Incyte Sinks On Setback For 2 Drugs Acquired In $750M Buyout: Retail Chatter Hits One-Year High
Incyte Corp.'s ($INCY) stock plunged over 13% on Tuesday after the biopharma company announced setbacks with two drugs ...
BioPharma Dive18 小时
Incyte sinks on setback for drugs acquired in $750M buyout
The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...
Celldex Therapeutics Reports Q3 2024 Progress and Financials
Celldex Therapeutics ( (CLDX) ) has released its Q3 earnings. Here is a breakdown of the information Celldex Therapeutics presented to its ...
WTOP News18 小时
Allergies: Types, Symptoms and How to Find Relief
More than 50 million Americans suffer from allergies — making allergies the sixth leading cause of chronic illness in the United States ... and others see symptoms return that require additional ...